Helicobacter pylori and immunotherapy for gastrointestinal cancer

[1]  J. Schenkel,et al.  Localization, tissue biology and T cell state — implications for cancer immunotherapy , 2023, Nature Reviews Immunology.

[2]  J. Ajani,et al.  Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses , 2023, Cancer Research.

[3]  K. Leung,et al.  Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. , 2023, The lancet. Gastroenterology & hepatology.

[4]  Wu Lili,et al.  Magnetic controlled capsule endoscope (MCCE)‘s diagnostic performance for H. pylori infection status based on the Kyoto classification of gastritis , 2022, BMC Gastroenterology.

[5]  Yao-dong Zhu,et al.  Helicobacter pylori infection and PD‐L1 expression in gastric cancer: A meta‐analysis , 2022, European journal of clinical investigation.

[6]  Xiaotian Zhang,et al.  Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment , 2022, Nature Communications.

[7]  D. Busch,et al.  Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature , 2022, medRxiv.

[8]  P. Ascierto,et al.  Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Shihe Shao,et al.  Helicobacter pylori promotes gastric cancer progression through the tumor microenvironment , 2022, Applied Microbiology and Biotechnology.

[10]  P. Gibbs,et al.  Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. , 2022, The Lancet. Oncology.

[11]  Z. Zeng,et al.  EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1 , 2022, Nature communications.

[12]  L. Shen,et al.  Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors , 2021, Journal of Hematology & Oncology.

[13]  M. Cuendet,et al.  Turning tumors from cold to inflamed to improve immunotherapy response. , 2021, Cancer treatment reviews.

[14]  R. Bourgon,et al.  Cross-tissue organization of the fibroblast lineage , 2021, Nature.

[15]  Thomas D. Wu,et al.  Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade , 2021, Journal for ImmunoTherapy of Cancer.

[16]  E. El-Omar,et al.  The interplay between Helicobacter pylori and gastrointestinal microbiota , 2021, Gut microbes.

[17]  L. Shen,et al.  Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers , 2020, Innovation.

[18]  V. Thorsson,et al.  Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  P. Portincasa,et al.  Mechanisms of the Epithelial–Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer , 2020, Cells.

[20]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Gail,et al.  Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial , 2019, BMJ.

[22]  C. Xie,et al.  A lucid review of Helicobacter pylori‐induced DNA damage in gastric cancer , 2019, Helicobacter.

[23]  Felicia L. Lenzo,et al.  Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients , 2019, Journal of Immunotherapy for Cancer.

[24]  J. Czyż,et al.  Role of Helicobacter pylori infection in cancer‐associated fibroblast‐induced epithelial‐mesenchymal transition in vitro , 2018, Helicobacter.

[25]  M. Vieth,et al.  Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer , 2018, Front. Cell. Infect. Microbiol..

[26]  I. Choi,et al.  Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer , 2018, The New England journal of medicine.

[27]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[28]  Heikki Joensuu,et al.  Gastrointestinal stromal tumour , 2013, The Lancet.

[29]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[30]  T. Rokkas,et al.  Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  M. Gail,et al.  Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. , 2006, Journal of the National Cancer Institute.

[32]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[33]  R. Peek,et al.  Pathobiology of Helicobacter pylori-Induced Gastric Cancer. , 2016, Gastroenterology.

[34]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .